Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.

Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.

Future Oncol. 2017 Nov 02;:

Authors: Joshi SS, Maron SB, Catenacci DV

Abstract
Pembrolizumab is a monoclonal antibody directed against PD-1 that is US FDA approved for treatment of advanced PD-L1 positive gastric and gastroesophageal junction adenocarcinoma in patients who have progressed on at least two prior lines of chemotherapy. This article summarizes the clinical evidence regarding safety, tolerability and efficacy of pembrolizumab in this setting. In addition, this article describes the investigational use of pembrolizumab as first- and second-line therapy and in combination with other treatments. Finally, this review compares other checkpoint inhibitors to pembrolizumab for the treatment of this disease, and explores predictive biomarkers of response to PD-1 blockade.

PMID: 29094609 [PubMed - as supplied by publisher]

from #PM All via ola Kala on Inoreader http://ift.tt/2Af1luc